Loading patent…
AssigneeSynthetic Biologics, Inc.
InventorsPertti KOSKI, Ulla AIRAKSINEN, Katja VALIMAKI
Estimating the term…
The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
A beta-lactamase comprising an amino acid sequence having at least 60% sequence identity with SEQ ID NO:
A method of modifying a beta-lactamase comprising an amino acid sequence having at least 60% sequence identity with SEQ ID NO:
The beta-lactamase or the method according to any one of the previous claims, characterized in that the hydrophilic amino acid at the position of SEQ ID NO:
The beta-lactamase or the method according to any one of the previous claims, characterized in that the beta-lactamase further comprises at least one amino acid selected from the group consisting of Leu220 and Arg244 according to Ambler classification.
The beta-lactamase or the method according to any one of the previous claims, characterized in that the beta-lactamase hydrolyses penicillins and/or cephalosporins.
The beta-lactamase or the method according to any one of the previous claims, characterized in that the beta-lactamase has improved catalytic efficiency on cephalosporins compared to wild type beta-latamases.
Dependencies are inferred from the claim text.